Erica Lyndrup Herzog MD, PhD

Associate Professor of Medicine (Pulmonary); Director, Translational Lung Research Program; Co-Director, Yale Fibrosis Program; Assistant Director, Medical Student Research, Department of Medicine; Director, Interstitial Lung Disease Center of Excellence

Clinical Interests

Interstitial lung disease, idiopathic pulmonary fibrosis, scleroderma, sarcoidosis, diffuse parenchymal lung disease


Board Certifications

2004
Pulmonary Disease, Board Certified
2006
Critical Care Medicine, Board Certified

Patient Care Locations

erica_herzogfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Alpha 1 Antitrypsin Deficiency and AATD(GRADS)(A) - Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis
Idiopathic Pulmonary Fibrosis(RAINIER) A Phase 2, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Assess the Efficacy and safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (GS-US-322-027)
Sarcoidosis(GRADS)(B) - Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidsosis
Idiopathic Pulmonary Fibrosis(GB28547) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis(BMS-IM136003) Clinical protocol IM136003 and efficacy of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of the safety and efficacy of BMS-986020 in subjects with IPF

More Clinical Trials...

Edit Profile